本文選題：結(jié)核分枝桿菌 + 耐藥結(jié)核病��； 參考：《現(xiàn)代預(yù)防醫(yī)學(xué)》2017年02期

【摘要】：目的了解近5年來南通市結(jié)核病的耐藥狀況,為制定切合該市結(jié)核病防控措施提供參考依據(jù)。方法對2009年10月1日-2014年6月30日該市培養(yǎng)陽性的1 893株分枝桿菌菌株運(yùn)用比例法進(jìn)行6種藥敏試驗(yàn)(異煙肼、利福平、乙胺丁醇、鏈霉素、氧氟沙星和卡那霉素),計(jì)算耐藥率。結(jié)果南通市結(jié)核分枝桿菌的總耐藥率、單耐藥率、多耐藥率、耐多藥率分別為21.34%、5.86%、3.17%、12.31%;復(fù)治患者總耐藥率高于初治(P0.01);男性患者總耐藥率和多耐藥率高于女性(P0.01);40~59歲中年組總耐藥率、耐多藥率高于其他年齡組(P0.01)。結(jié)論該市耐多藥結(jié)核病疫情防控形勢不容樂觀,應(yīng)提高初治患者治愈率,積極推廣應(yīng)用快速診斷新技術(shù)。通過對耐藥結(jié)核病患者的早發(fā)現(xiàn)、早診斷、早治療,并提供心理支持、健康教育等環(huán)節(jié),減少獲得性耐藥和原發(fā)性耐藥的發(fā)生。
[Abstract]:Objective to investigate the drug resistance status of tuberculosis in Nantong City in recent 5 years and to provide reference basis for the establishment of tuberculosis prevention and control measures in Nantong City. Methods six drug susceptibility tests (isoniazid, rifampicin, ethambutanol, streptomycin) were carried out on 1 893 strains of Mycobacterium in the city from October 1, 2009 to June 30, 2014. Ofloxacin and kanamycin were calculated for drug resistance. Results the total drug resistance rate, single drug resistance rate, multidrug resistance rate and multidrug resistance rate of Mycobacterium tuberculosis in Nantong City were 21.34 and 5.86 respectively. The total drug resistance rate of patients with recurrent treatment was higher than that of P0.01A, and the total drug resistance rate of male patients was higher than that of female patients aged 4059 years. The rate of multidrug resistance was higher than that of other age groups (P 0.01). Conclusion the situation of prevention and control of MDR-TB in this city is not optimistic, the cure rate should be improved and the new technique of rapid diagnosis should be popularized. In order to reduce the occurrence of acquired drug resistance and primary drug resistance, early detection, early diagnosis, early treatment, psychological support, health education and so on were used to reduce the incidence of acquired drug resistance and primary drug resistance in patients with drug-resistant tuberculosis.
【作者單位】： 南通市疾病預(yù)防控制中心;
【基金】：南通市社會發(fā)事業(yè)科技創(chuàng)新與示范項(xiàng)目(編號:HS149001) 第七輪中國全球基金結(jié)核病項(xiàng)目(CHN-708-G11-T)
【分類號】：R52

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 馬偉路,羅智;耐藥和耐多藥結(jié)核病及其控制[J];臨床肺科雜志;2000年01期

2 于維琴;耐多藥結(jié)核病的處理[J];臨床肺科雜志;2000年03期

3 曾國武;78例耐多藥結(jié)核病臨床分析[J];醫(yī)學(xué)文選;2000年05期

4 何國鈞;新世紀(jì)耐多藥結(jié)核病分子生物學(xué)診斷的重要性[J];中華傳染病雜志;2001年06期

5 肖成志,李群輝,李拯民,傅瑜;耐多藥結(jié)核病的治療[J];臨床肺科雜志;2001年03期

6 全國結(jié)核病胸部疾病科研協(xié)作組;耐多藥結(jié)核病治療的研究方案[J];臨床肺科雜志;2001年03期

7 C.Conover,R.Ridzon,S.Valway,L.Schoenstadt,J.McAuley,I.Onorato,W.Paul,an investigative team ,王海東;美沙酮治療規(guī)程中耐多藥結(jié)核病的暴發(fā)[J];結(jié)核與肺部疾病雜志(中文版);2001年02期

8 陸強(qiáng),王樞傳;耐多藥結(jié)核病的研究進(jìn)展[J];天津藥學(xué);2002年01期

9 李一耕;我國耐多藥結(jié)核病研究的現(xiàn)狀與思考[J];新醫(yī)學(xué);2003年11期

10 張立興 ,屠德華;加強(qiáng)預(yù)防和合理治療耐多藥結(jié)核病[J];中國防癆雜志;2003年01期

相關(guān)會議論文 前10條

1 馬s，

本文編號：1864178